Combination Therapies in Melanoma
Omid Hamid, MD, discusses promising combination therapies for the treatment of melanoma.
Omid Hamid, MD, chief, translational research and immunotherapy, director, cutaneous oncology and melanoma, The Angeles Clinic and Research Institute, discusses promising combination therapies for the treatment of melanoma.
Clinical Pearls
- In the metastatic setting, BRAF, MEK, and checkpoint inhibition is forthcoming
- There are currently trials looking at anti-PD-1 with anti-CTLA-4 therapy
- Dr. Hamid is hopeful that in the future, other targeted immunotherapies and FDA-approved targeted treatment combinations will show survival benefit and be approved and available for use.
Recent Videos
Related Content
Post–PD-1 Data in Melanoma Offers Insight into IO Approaches
February 13th 2025Article
During a Case-Based Roundtable® event, Thach-Giao Truong, MD, discussed goals and barriers to treatment when using combination immunotherapy for metastatic melanoma in the second article of a 2-part series.
Read More
